Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19116694 | 0.92 | TP53BP1 (0.47) | TP53BP1CTSLEPHX2ALOX5GPR139 | |
| SCHEMBL19121150 | 0.83 | CTSL (0.45) | TP53BP1CTSLGPR139KMT2AGAA | |
| SCHEMBL19440384 | 0.82 | TP53BP1 (0.40) | TP53BP1CTSLKMT2AGAAHSD17B10 | |
| SCHEMBL25947864 | 0.80 | TP53BP1 (0.49) | TP53BP1CTSLEPHX2ALOX5GPR139 | |
| SCHEMBL17658901 | 0.79 | TP53BP1 (0.61) | TP53BP1CTSLEPHX2ALOX5GPR139 | |
| SCHEMBL13122905 | 0.74 | SLC6A3 (0.40) | TP53BP1CTSLEPHX2ALOX5KMT2A | |
| SCHEMBL16884654 | 0.70 | HPGD (0.49) | TP53BP1EPHX2KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL24904269 | 0.69 | HPGD (0.58) | EPHX2KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL20759290 | 0.69 | ALDH1A1 (0.44) | TP53BP1CTSLPRKD1SMN1; SMN2 | |
| SCHEMBL12756951 | 0.68 | NPC1 (0.61) | CTSLKMT2AGAAHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TP53BP1 3917/4885CTSL 3540/4885EPHX2 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.